Ibrahim Nassour, MD, MSCS - Research

Research at a glance

Top areas of exploration

Pancreatic Neoplasms , 23 publications
Adenocarcinoma , 17 publications
Robotic Surgical Procedures , 12 publications
Pancreaticoduodenectomy , 12 publications

Research activity

92 publications

1,522 citations

Why is this important?

Active clinical trials

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy鈥�

Investigator: Ibrahim Nassour
Status: Accepting Candidates
Ages: 18 Years - N/A
Sexes: All

Compare Chemo Before and After Surgery vs After Surgery Alone for the TX of Gallbladder Cancer

This phase II/III trial compares the effect of adding chemotherapy before and after surgery versus after surgery alone (usual treatment) in treating patients with stage II-III gallbladder cancer. Chemotherapy drugs, such as gemcitabine and鈥�

Investigator: Ibrahim Nassour
Status: Accepting Candidates
Ages: 18 Years - N/A
Sexes: All

My publications

92 publications

2024

Analysis of pancreatic cancer treatment and survival disparities in Florida throughout the Covid-19 pandemic.

Journal of the National Medical Association

鈥�

2024

Correction to: Lenvatinib inhibits the growth of gastric cancer patient鈥慸erived xenografts generated from a heterogeneous populations.

Journal of translational medicine

鈥�

2024

Patient Outcomes in Resected Combined Hepatocellular Cholangiocarcinoma (cHCC-ICC) and Intrahepatic Cholangiocarcinoma: A Single Center Study

Cancers

鈥�

2024

Postoperative infectious complications worsen oncologic outcomes following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.

Journal of surgical oncology

鈥�

2023

A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma.

Future oncology (London, England)

鈥�

BOB体育